WYPB .028 showing some strength on decent volume. In July, it was as high as .04.
WayPoint Biomedical Revenues Over 300% Ahead of Previous Quarter -- WayPoint Secures National Distribution Agreements and Posts Early Sales for Urine Reagent Strip Business
Wednesday September 21, 4:15 pm ET
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 21, 2005 -- WayPoint Biomedical, Inc. has secured initial sales and stocking orders that have boosted Company revenues over 300% ahead of the previous quarter. WayPoint has completed national distribution agreements for their WayPoint branded Urine Reagent Strip (URS) Line. They have also signed and initiated private label programs with two nationally recognized laboratory supply companies for WayPoint's Urine Reagent Test Strips.
Neil Schneider, WayPoint's National Clinical Sales Manager, states, "The Urine Reagent Strip business is a very important facet of our Clinical Point of Care product group and I am delighted with the early success." Mr. Schneider adds, "There has been a consistently positive response to our URS product offering by key distribution groups, and the interest in our private label programs has been quite encouraging. I believe WayPoint's URS group of products has the potential to generate up to $750,000 in revenue over the first year."
The overall USA market size for the Urine Reagent Strip business is estimated to be close to $150,000,000.
About WayPoint Biomedical:
WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Other OTC:WYPB.PK - News), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.
Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
Contact:
Contacts:
Dennis Shepherd
714-848-3200
E-mail: Email Contact
IR Firm:
Corporate Awareness Professionals, Inc.
Hank Zemla
586-228-2290
E-mail: Email Contact
--------------------------------------------------------------------------------
Source: WayPoint Biomedical Holdings, Inc. |
